The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence

• Status: Withdrawn
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a randomized, double blinded placebo controlled trial over a period of 3 months. Study subjects will be randomized into 2 groups: Those receiving drug (1gm of estrogen vaginal cream [EVC] at bed time 3 times a week), and those receiving placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine
• Treatments: Estrogens

Criteria

Inclusion Criteria:

• English speaking

• Postmenopausal women (No menses for a minimum period of 1 year)

• Urodynamic stress urinary incontinence

Exclusion Criteria:

• History of breast or uterine cancer

• History of venous thrombolic event

• Hormone replacement therapy within 3 months of study

• Sensitivity or allergy to premarin cream

• Current use of any medications for urge or stress incontinence

• Prior surgery for stress incontinence

• Overactive bladder or Detrussor instability

• Active vaginal/ bladder infection (patients will be treated and have a negative test for cure in order to be enrolled in the study)

• History of pelvic or vaginal radiation therapy